Theralase Technologies Inc. (CVE:TLT – Get Free Report)’s stock price was up 13% on Monday . The stock traded as high as C$0.26 and last traded at C$0.26. Approximately 142,156 shares changed hands during trading, a decline of 52% from the average daily volume of 295,527 shares. The stock had previously closed at C$0.23.
Theralase Technologies Stock Performance
The stock has a 50-day moving average of C$0.28 and a 200-day moving average of C$0.24. The firm has a market cap of C$71.71 million, a price-to-earnings ratio of -16.25 and a beta of -0.33. The company has a debt-to-equity ratio of 25.76, a quick ratio of 3.40 and a current ratio of 1.25.
About Theralase Technologies
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.
Read More
- Five stocks we like better than Theralase Technologies
- SpaceX Gets the Attention, But These 4 Stocks Could Get the Returns
- Microsoft Stock Discount May Be Ending as AI Catalysts Build
- Apparel Earnings Winners and Losers: Ralph Lauren Takes Off
- Why Walmart, Target and TJX Got Such Different Reactions After Earnings
Receive News & Ratings for Theralase Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
